Prospects and challenges of clinical application of biomarkers in patients with heart failure in precision medicine
10.3760/cma.j.cn114452-20230811-00055
- VernacularTitle:精准医学背景下心力衰竭患者生物标志物临床应用的前景及挑战
- Author:
Kegang JIA
1
Author Information
1. 天津医科大学心血管病临床学院 泰达国际心血管病医院检验科，天津 300457
- Keywords:
Heart failure;
Biomarker;
Heterogeneity;
Precision medicine
- From:
Chinese Journal of Laboratory Medicine
2023;46(12):1217-1223
- CountryChina
- Language:Chinese
-
Abstract:
The arrival of the era of precision medicine has opened a new diagnosis and treatment model for heart failure (HF), and the development of various omics technologies has also promoted the research and clinical application of HF precision phenotype. HF patients are affected by many factors such as gender, age, height, weight, drugs, valvular disease, etc. At the same time, its disease course is long and complex, and different HF types and stages also affect the treatment and prognosis of patients. Therefore, a variety of new biomarkers are urgently needed in clinic to meet the needs of individualized HF diagnosis and treatment. With the latest advances in epigenetics, proteomics, metabolomics and microbiology, it provides a beneficial complementary effect of "addition" for the study of HF individual heterogeneity. The existing application problems and limitations of various types of markers are discussed. For the future, the integration of all personalized omics data offers unlimited potential for precision medicine in patients with HF.
